NASDAQ:IMTX Immatics (IMTX) Stock Price, News & Analysis $12.30 -0.09 (-0.73%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$12.26▼$12.6150-Day Range$9.82▼$13.4952-Week Range$7.15▼$13.77Volume308,287 shsAverage Volume494,061 shsMarket Capitalization$1.04 billionP/E RatioN/ADividend YieldN/APrice Target$16.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Immatics alerts: Email Address Immatics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside30.1% Upside$16.00 Price TargetShort InterestBearish11.80% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.72Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.25) to ($1.41) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.07 out of 5 starsMedical Sector819th out of 936 stocksBiological Products, Except Diagnostic Industry141st out of 154 stocks 3.5 Analyst's Opinion Consensus RatingImmatics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageImmatics has only been the subject of 1 research reports in the past 90 days.Read more about Immatics' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted11.80% of the outstanding shares of Immatics have been sold short.Short Interest Ratio / Days to CoverImmatics has a short interest ratio ("days to cover") of 20, which indicates bearish sentiment.Change versus previous monthShort interest in Immatics has recently increased by 4.72%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldImmatics does not currently pay a dividend.Dividend GrowthImmatics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IMTX. Previous Next 2.6 News and Social Media Coverage News SentimentImmatics has a news sentiment score of 0.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Immatics this week, compared to 1 article on an average week.MarketBeat FollowsOnly 1 people have added Immatics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Immatics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.30% of the stock of Immatics is held by insiders.Percentage Held by Institutions64.41% of the stock of Immatics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Immatics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Immatics are expected to decrease in the coming year, from ($1.25) to ($1.41) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Immatics is -11.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Immatics is -11.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioImmatics has a P/B Ratio of 4.27. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Immatics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED will cut rates any day now. But there's one indicator that's flashing a BIG warning sign to investors.Take these 4 steps to protect your retirement here. About Immatics Stock (NASDAQ:IMTX)Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.Read More IMTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IMTX Stock News HeadlinesJuly 25 at 10:44 AM | finance.yahoo.comInvestors in Immatics (NASDAQ:IMTX) have seen returns of 24% over the past five yearsJuly 22, 2024 | markets.businessinsider.comHere's Why 'Trend' Investors Would Love Betting on ImmaticsJuly 26, 2024 | Porter & Company (Ad)We recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…July 19, 2024 | finance.yahoo.comImmatics Announces Upcoming Oral Presentation at ESMO Congress 2024May 21, 2024 | finance.yahoo.comHere's Why We're Not Too Worried About Immatics' (NASDAQ:IMTX) Cash Burn SituationMay 16, 2024 | markets.businessinsider.comBuy Rating Affirmed for Immatics on Strong TCR-T Cell Therapy Data and Promising OutlookMay 16, 2024 | msn.comStock Market News for May 15, 2024May 14, 2024 | globenewswire.comImmatics Announces First Quarter 2024 Financial Results and Business UpdateJuly 26, 2024 | Porter & Company (Ad)We recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…March 29, 2024 | markets.businessinsider.comMaintained Buy Rating for Immatics Amid Robust Clinical Pipeline and Promising PartnershipsMarch 21, 2024 | investorplace.comIMTX Stock Earnings: Immatics Beats EPS, Beats Revenue for Q4 2023March 21, 2024 | globenewswire.comImmatics Announces Full Year 2023 Financial Results and Corporate UpdateMarch 15, 2024 | finance.yahoo.comWith 52% institutional ownership, Immatics N.V. (NASDAQ:IMTX) is a favorite amongst the big gunsMarch 10, 2024 | seekingalpha.comCantor sees strong year ahead for oncology M&AMarch 10, 2024 | msn.comCantor Fitzgerald sees strong year ahead for oncology M&AMarch 7, 2024 | markets.businessinsider.comBuy Rating Affirmed for Immatics on Promising TCR-Based Cancer Therapies and Strategic PartnershipsFebruary 28, 2024 | seekingalpha.comEditas Medicine: Several Catalysts For Reni-Cel In 2024 Make This A Must WatchFebruary 6, 2024 | uk.yahoo.comBolton TV star to 'go back to Fernandos one last time' as he spreads the loveSee More Headlines Receive IMTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immatics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2024Today7/26/2024Next Earnings (Estimated)8/15/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:IMTX CUSIPN/A CIK1809196 Webwww.immatics.com Phone4.97072E+12FaxN/AEmployees432Year FoundedN/APrice Target and Rating Average Stock Price Target$16.00 High Stock Price Target$16.00 Low Stock Price Target$16.00 Potential Upside/Downside+29.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.06) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-104,980,000.00 Net Margins-107.80% Pretax Margin-106.01% Return on Equity-29.36% Return on Assets-15.95% Debt Debt-to-Equity RatioN/A Current Ratio3.95 Quick Ratio3.95 Sales & Book Value Annual Sales$58.44 million Price / Sales17.93 Cash FlowN/A Price / Cash FlowN/A Book Value$2.88 per share Price / Book4.30Miscellaneous Outstanding Shares84,660,000Free Float81,864,000Market Cap$1.05 billion OptionableOptionable Beta0.75 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesDr. Harpreet Singh Ph.D. (Age 49)CEO, MD, Member of Management Board & Executive Director Comp: $896.49kDr. Toni Weinschenk Ph.D. (Age 50)Co-Founder & Chief Innovation Officer Mr. Arnd Christ MBA (Age 58)Chief Financial Officer Mr. Steffen Walter Ph.D. (Age 47)Chief Operations Officer Mr. Edward A. Sturchio J.D. (Age 48)General Counsel & Secretary Dr. Carsten Reinhardt M.D. (Age 57)Ph.D., Chief Development Officer Mr. Cedrik M. Britten M.D. (Age 48)Chief Medical Officer Mr. Jordan Silverstein (Age 44)Head of Strategy Dr. Hans-Georg Rammensee Ph.D.Co-Founder & Member of the Scientific Advisory BoardMr. Ephraim Hofsäß M.Sc.Vice President of SEC Reporting & AccountingMore ExecutivesKey CompetitorsImmunovantNASDAQ:IMVTImmunityBioNASDAQ:IBRXTwist BioscienceNASDAQ:TWSTArcellxNASDAQ:ACLXDenali TherapeuticsNASDAQ:DNLIView All CompetitorsInstitutional OwnershipAlphaCentric Advisors LLCBought 2,500 shares on 7/26/2024Ownership: 0.024%RA Capital Management L.P.Bought 1,750,000 shares on 5/17/2024Ownership: 2.067%Zimmer Partners LPBought 187,000 shares on 5/17/2024Ownership: 0.469%Janus Henderson Group PLCSold 66,437 shares on 5/16/2024Ownership: 0.754%Lazard Asset Management LLCSold 2,474 shares on 5/15/2024Ownership: 0.007%View All Institutional Transactions IMTX Stock Analysis - Frequently Asked Questions How have IMTX shares performed this year? Immatics' stock was trading at $10.53 on January 1st, 2024. Since then, IMTX shares have increased by 16.8% and is now trading at $12.30. View the best growth stocks for 2024 here. How were Immatics' earnings last quarter? Immatics (NASDAQ:IMTX) announced its quarterly earnings data on Tuesday, May, 14th. The company reported ($0.04) EPS for the quarter, topping analysts' consensus estimates of ($0.74) by $0.70. The firm earned $32.87 million during the quarter, compared to the consensus estimate of $17.76 million. Immatics had a negative net margin of 107.80% and a negative trailing twelve-month return on equity of 29.36%. Who are Immatics' major shareholders? Immatics' top institutional investors include AlphaCentric Advisors LLC (0.02%). How do I buy shares of Immatics? Shares of IMTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Immatics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Immatics investors own include Advanced Micro Devices (AMD), Chimerix (CMRX), Datadog (DDOG), Forte Biosciences (FBRX) and This page (NASDAQ:IMTX) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immatics Please log in to your account or sign up in order to add this asset to your watchlist. Share Immatics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IMTX Stock Alerts